Zanubrutinib-induced liver injury: a case report and literature review
(2021)
Journal Article
Background: Zanubrutinib is a Bruton’s tyrosine kinase inhibitor that has been recently licensed in refractory mantle cell lymphoma and under assessment in phase 3 clinical trials for other B cell malignancies. To date, there are no reported cases of... Read More about Zanubrutinib-induced liver injury: a case report and literature review.